Free Trial

Nektar Therapeutics (NKTR) Competitors

Nektar Therapeutics logo
$25.00 +0.42 (+1.71%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$24.98 -0.02 (-0.06%)
As of 07/25/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NKTR vs. PCRX, OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMY

Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry.

Nektar Therapeutics vs. Its Competitors

Pacira BioSciences (NASDAQ:PCRX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Pacira BioSciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Pacira BioSciences has a net margin of -14.78% compared to Nektar Therapeutics' net margin of -152.49%. Pacira BioSciences' return on equity of 13.78% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pacira BioSciences-14.78% 13.78% 7.00%
Nektar Therapeutics -152.49%-329.54%-55.24%

Pacira BioSciences has higher revenue and earnings than Nektar Therapeutics. Pacira BioSciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$700.97M1.49-$99.56M-$2.28-9.89
Nektar Therapeutics$98.43M3.15-$118.96M-$9.60-2.60

Pacira BioSciences currently has a consensus price target of $27.00, suggesting a potential upside of 19.73%. Nektar Therapeutics has a consensus price target of $88.33, suggesting a potential upside of 253.33%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Pacira BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pacira BioSciences
1 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.44
Nektar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by company insiders. Comparatively, 5.3% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Pacira BioSciences had 8 more articles in the media than Nektar Therapeutics. MarketBeat recorded 11 mentions for Pacira BioSciences and 3 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 1.10 beat Pacira BioSciences' score of 0.17 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pacira BioSciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nektar Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Pacira BioSciences beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Nektar Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKTR vs. The Competition

MetricNektar TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$304.96M$2.50B$5.70B$9.50B
Dividend YieldN/A1.75%4.69%4.01%
P/E Ratio-2.619.0528.1020.06
Price / Sales3.15592.38428.3588.93
Price / CashN/A165.2136.2258.56
Price / Book5.065.168.665.87
Net Income-$118.96M$30.99M$3.25B$258.55M
7 Day Performance0.24%7.74%4.22%3.73%
1 Month Performance-15.77%16.27%10.51%11.75%
1 Year Performance20.77%-1.88%34.40%18.02%

Nektar Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTR
Nektar Therapeutics
3.9837 of 5 stars
$25.00
+1.7%
$88.33
+253.3%
+21.7%$304.96M$98.43M-2.61220
PCRX
Pacira BioSciences
3.3276 of 5 stars
$22.62
-0.5%
$26.44
+16.9%
+12.9%$1.05B$702.77M-9.95720News Coverage
Upcoming Earnings
Analyst Upgrade
OMER
Omeros
4.049 of 5 stars
$3.51
-2.9%
$18.00
+413.3%
-27.5%$206.71MN/A-1.33210Trending News
Analyst Forecast
Options Volume
Analyst Revision
Gap Up
ASMB
Assembly Biosciences
3.7705 of 5 stars
$18.55
-0.5%
$33.00
+77.9%
+25.0%$141.69M$28.52M-2.98100
CPIX
Cumberland Pharmaceuticals
0.8785 of 5 stars
$3.68
+5.1%
N/A+141.1%$55.05M$37.87M-14.7280
LLY
Eli Lilly and Company
4.9051 of 5 stars
$785.69
+1.8%
$1,012.56
+28.9%
-1.3%$744.67B$45.04B63.9347,000Trending News
Analyst Upgrade
JNJ
Johnson & Johnson
4.839 of 5 stars
$163.63
+5.5%
$171.00
+4.5%
+5.4%$393.55B$88.82B18.19138,100Trending News
Analyst Upgrade
ABBV
AbbVie
4.8458 of 5 stars
$190.00
+1.9%
$211.29
+11.2%
+4.4%$335.14B$56.33B80.7455,000Trending News
Upcoming Earnings
Analyst Revision
MRK
Merck & Co., Inc.
4.9947 of 5 stars
$82.27
+0.9%
$108.69
+32.1%
-32.6%$206.51B$63.92B11.9775,000Positive News
Upcoming Earnings
Dividend Announcement
PFE
Pfizer
4.9812 of 5 stars
$24.83
+0.9%
$28.55
+15.0%
-18.0%$141.14B$63.63B17.9981,000Trending News
Options Volume
BMY
Bristol Myers Squibb
4.5657 of 5 stars
$47.09
+1.4%
$57.69
+22.5%
+7.0%$95.82B$48.30B17.6334,100Trending News
Upcoming Earnings

Related Companies and Tools


This page (NASDAQ:NKTR) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners